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INTRODUCTION
Allogeneic hematopoietic cell transplantation (HCT) is
curative for patients with many hematologic malignancies
and other nonmalignant disorders [1-3]. The current prac-
tice of HCT involves elimination of recipient blood-forming
cells using high-dose chemoradiation followed by transfer of
healthy donor hematopoietic cells. Hematopoietic grafts
contain heterogeneous mixtures of cells at various matura-
tional stages, including a rare population of hematopoietic
stem cells (HSCs). Because HSCs are pluripotent and self-
renewing, only they can permanently regenerate all blood
cell lineages and, hence, are the only cells needed to engraft
in an HCT procedure [4]. However, a major beneﬁt of allo-
geneic HCT is the graft-versus-tumor (GVT) effect
wherein mature immune cells, primarily T lymphocytes,
contained within the hematopoietic graft exert cytotoxic or
suppressive actions against residual tumor cells that survive
the myeloablative regimens [5-7]. Unfortunately, T cells
also mediate the potentially lethal complication of graft-
versus-host disease (GVHD), which develops if donor
T cells respond against normal recipient tissues [8,9].
One approach to overcoming these problems of HCT is
to engineer grafts to contain HSCs plus other cell popula-
tions that exert GVT effects without GVHD. HSCs can be
puriﬁed from mouse and human bone marrow or cytokine-
mobilized peripheral blood using labeled monoclonal anti-
bodies (MoAbs) and cell sorting [4,10-12]. In recent clinical
trials, such phenotypically purified autologous HSCs
demonstrated rapid and sustained engraftment in patients
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ABSTRACT
A major benefit of allogeneic hematopoietic cell transplantation (HCT) in the treatment of malignancies is the graft-
versus-tumor (GVT) effect conferred by lymphocytes contained within the graft. However, lymphocytes can also
induce the potentially lethal complication of graft-versus-host disease (GVHD). We have previously reported a
method of generating large numbers of ex vivo activated and expanded T cells with antitumor activity after culture
with interferon-γ, cross-linking antibodies to CD3, and interleukin-2. Murine splenocytes expanded under these con-
ditions are a heterogeneous population of which approximately 20% to 60% of cells express natural killer (NK)-cell
markers (NK1.1 and DX5) and display major histocompatibility complex (MHC)-unrestricted antitumor activity.
Here we demonstrate the in vivo antitumor activity of this population of expanded CD8+ NK-T cells when trans-
planted across MHC barriers into tumor-bearing hosts. In cotransfer studies with purified allogeneic hematopoietic
stem cells, expanded CD8+ NK-T cells confer GVT activity with minimal to no GVHD. In vitro studies show that,
although expanded NK-T cells lyse normal allogeneic bone marrow cells, they preferentially mediate cytolysis
against tumor targets. These cells persist in the peripheral circulation of host animals for at least 3 weeks posttrans-
fer. GVT activity is dependent on perforin, but not on Fas-ligand. We conclude that expanded CD8+ NK-T cells may
serve as a valuable adjuvant population for allogeneic HCT because they mediate GVT effects with minimal GVHD.
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who underwent transplantations for a variety of malignan-
cies [12-14]. Puriﬁed HSCs are immunologically naive and
therefore will not cause GVHD. However, as we recently
showed in a mouse model, allogeneic HSCs are devoid of
measurable GVT activity [15]. Thus, we [15-18] and others
[5-7,19,20] have pursued clinically feasible methodologies to
obtain cell populations that mediate GVT activity without
GVHD. Many of these approaches require large quantities
of cells and extensive technical manipulations to generate
tumor specific populations, thereby limiting their general
applicability to patients.
We previously described, for both mice [21] and humans
[16,22], a population of ex vivo expanded lymphoid cells
that demonstrate in vitro cytotoxicity against a variety of
syngeneic and allogeneic tumors, without having had prior
exposure. These cells are derived from peripheral blood
lymphocytes (PBLs) that are cultured with timed addition of
growth factors and cross-linking anti-CD3 MoAbs. After
approximately 3 weeks in culture, a phenotypically homoge-
neous population (>90%) expands that expresses CD3,
CD8, and the T-cell receptor (TCR) α/β, and 20% to 60%
of cells express natural killer (NK)-cell markers, resulting in
a >100- to 1000-fold expansion of this otherwise rare popu-
lation of cells [21]. Here, we report on the in vivo activity
of expanded CD8+ NK-T cells in a murine model of persis-
tent lymphoma following transplantation of purified allo-
geneic HSCs. Expanded CD8+ NK-T cells demonstrate
signiﬁcant GVT activity with minimal to no GVHD, even
when transplanted across major histocompatibility complex
(MHC) barriers. The expanded cells can be detected in the
peripheral circulation for weeks and require an intact per-
forin-dependent cytolytic pathway to confer protection
from lymphoma growth. Our studies show that expanded
CD8+ NK-T cells are a phenotypically unique population
that appears to have innate tumor immunity but are not
pan-reactive to alloantigens.
MATERIALS AND METHODS
Mice
Recipient mice were 7- to 10-week-old BALB/c mice
(H-2d, Thy-1.2). Thy-1.1 congenic C57BL/Ka.Thy-1.1
mice (H-2b, Thy-1.1, CD45.2) were used as allogeneic
HSC and CD8+ NK-T cell donors. In selected studies,
C57BL/Ka.Thy-1.2 mice congenic at the Thy-1.2 and
CD45 loci (H-2b, Thy-1.2, CD45.1) were used as CD8+
NK-T cell donors. Target cells for the ﬂuorescence-activated
cell sorting (FACS)-based killing assay were obtained from
C57BL/Ka.Thy-1.1 or BALB/c mice. Mice were bred at
Stanford University (Department of Comparative Medi-
cine). In selected studies, the following immune-defective
mice were used as donors for expanded CD8+ NK-T cells:
perforin-knockout (C57BL/6-PfptmlSdz) and Fas ligand
(FasL)-mutant mice (B6Smn: Fasgld) (Jackson Laboratories,
Bar Harbor, ME). All mice were maintained in specific
pathogen-free conditions in temperature-controlled and
light-cycled rooms.
Expansion of CD8+ NK-T Cells
Single-cell suspensions were prepared from donor
splenocytes. Cells were cultured in RPMI 1640 media supple-
mented with 10% fetal calf serum (FCS), 2 mmol/L L-gluta-
mine, 100 U/mL penicillin, 100 mg/mL streptomycin, and
50 mmol/L 2-mercaptoethanol. Murine interferon-γ (IFN-
γ) (Genetics Institute, Cambridge, MA), 1000 U/mL, was
added on day 1. After 24 hours, the cells were transferred to
ﬂasks coated with 50 ng/mL of the anti-CD3 MoAb (145-
2C11; Pharmingen, San Diego, CA) and 300 IU/mL of
human recombinant interleukin-2 (rIL-2) (Chiron,
Emeryville, CA). The cultured cells were supported with
fresh media and rhIL-2 every 2 to 3 days.
Morphology Analysis
Expanded CD8+ NK-T cells (106 cells) were suspended
in 100 µL phosphate buffered saline (PBS) and cytospun at
800 rpm onto bovine serum albumin–coated glass slides.
The cytospun cells were stained with Wright-Giemsa stain.
Phenotype Analysis
FACS analysis of either splenocytes or expanded CD8+
NK-T cells was performed. For analysis of unactivated
splenocytes, 6- to 10-week-old C57BL/Ka.Thy-1.1 mice
were killed and their splenocytes isolated. Red blood cells
were removed using osmotic lysis (ACK), and the remaining
cells were washed with FACS staining buffer consisting of
PBS supplemented with 2% FCS. In experiments using
expanded CD8+ NK-T cells, cells were washed with FACS
buffer (as above). To prevent nonspeciﬁc antibody binding,
cells were first treated for 15 minutes with Fc receptor
blocking antibodies (α-CD16/CD32, Pharmingen). The
cells were then stained for 15 to 30 minutes with either
fluorescein isothiocyanate (FITC)- or phycoerythrin (PE)-
conjugated MoAbs directed against CD3 (145-2C11), CD8
(Ly 3.2, 53-5.8), TCRγ/δ (GL3), NK1.1 (Ly 55, PK136),
TCRα/β (Η57−597), Ly49A (A1), Ly49C/I (5E6), Ly49D
(4E5), Ly49F (HBF-719), Ly49G2 (4D11), Ly49I (YLI-90),
and NKG2A/C/E (20d5) or appropriate isotype controls (all
from Pharmingen). In select experiments (multicolor FACS
analysis), CD3-allophycocyanin (145-2C11; Pharmingen),
CD8–Texas red (Ly 3.2, 53-5.8) (gift from Irving Weissman,
Stanford University, Stanford CA), CD94-biotin (18d3) and
second-step strepavidin-PE (Pharmingen), and neutra-
Avidin-cascade blue (Molecular Probes, Eugine, OR) were
used. Excess antibody was washed off and cells were resus-
pended in FACS staining buffer. Propidium iodine (PI;
Sigma, St. Louis, MO) was added at 1 mg/mL to allow
exclusion of dead cells. Cells were analyzed using either a
single-laser FACScan or a triple-laser FACS instrument
(with Moflops electronics) that was modified and made
available through the FACS shared-user group at Stanford
University. Data analysis was performed using Flowjo (Tree
Star Inc, San Carlos, CA), version 3.2.
HSC Purification
Purified HSCs were obtained by modification of the
methods described by Spangrude et al. [10]. MoAbs were
the kind gift of Dr. I. Weissman (Stanford University, Stan-
ford, CA), with the exceptions of anti-CD3 MoAb (145-
2C11) and anti-CD8 MoAb (53-6.7) which were obtained
from Pharmingen. Bone marrow (BM) was obtained from
donor mice by ﬂushing tibiae and femurs with Hanks Bal-
anced Salt Solution (HBSS; Applied Scientiﬁc, San Francisco,
M.R. Verneris et al.
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CA) supplemented with 2% FCS. BM cells were positively
selected for biotin-conjugated Sca-1 using the Mini-
MACS/MidiMACS separation system (Miltenyi Biotech,
Auburn, CA). The retained Sca-1–enriched fraction was
eluted and stained with FITC-conjugated α-Thy1.1
(19xE5) and a mixture of PE-conjugated lineage-specific
MoAbs as follows: α-B220 (6B2), α-CD3 (145-2C11),
α-CD5 (53-7.8), α-CD4 (GK-1.5), α-CD8 (53-6.7), GR-1
(8C5), α-Mac-1 (M1/70), and α-TER119 (TER199). Cells
were stained with MoAbs directed against c-kit (2B8) and
Sca-1 that were labeled with allophycocyanin and Texas
red, respectively. Cells were suspended in HBSS with 2%
FCS, and 1 mg/mL PI was added. The labeled cells were
analyzed and sorted on a dual-laser FACS (Becton Dickin-
son Immunocytometry Systems, Mountain View, CA), that
was modiﬁed and made available through the FACS shared-
user group at Stanford University. Cells were sorted for
Thy-1loLin–/loSca+c-Kit+, and the purity was verified by
FACS reanalysis.
Hematopoietic Cell and Expanded CD8+ NK-T Cell
Transplantation
Recipient BALB/c mice were prepared for transplanta-
tion using a 250/kV x-ray machine at 100 rad/min in 2 split
doses (4 Gy each) with a 3- to 4-hour interval. After irradia-
tion, mice were maintained on antibiotic water containing
polymyxin B sulfate and neomycin sulfate. The recipient
mice were injected with 6000 puriﬁed HSCs (0.1-0.2 mL/
injection) via the tail vein. Mice receiving expanded CD8+
NK-T cells were also injected via the tail vein 1 day after
the HSC inoculation.
Assessment of peripheral blood chimerism involved
2-color immunoﬂuoresence. Donor cells were distinguished
from host cells using MoAbs speciﬁc for the MHC class I of
donor mice (H-2b) and lineage-speciﬁc markers for B cells
(B220), myeloid cells (GR.1), or monocytes (Mac-1). T cells
of donor or host were distinguished by staining for Thy-1.1
versus Thy-1.2.
BCL1 Tumor Inoculation
The B-cell lymphoma BCL1 line (H-2
d) [23-25] was the
kind gift of Dr. R. Levy (Stanford University) and main-
tained by in vivo passage in BALB/c mice. Recipient mice
were injected with 103 BCL1 tumor cells via tail vein 1 week
prior to transplantation.
Proliferation Assay
Responder cells were expanded CD8+ NK-T cells, derived
from C57BL/Ka.Thy-1.1 (H-2b) mice, that were removed at
different times in culture (days 0, 7, 14, and 21) and tested for
proliferation against irradiated (3000 cGy) stimulator cells,
which were either syngeneic C57BL/Ka.Thy-1.1 (H-2b) or
allogeneic BALB/c (H-2d) splenocytes. Responder and stim-
ulator cells were suspended in complete RPMI (cRPMI) and
added to 96-well ﬂat-bottom plates. The responder cell dose
was 105/well and stimulators were added at ratios of 1:1, 1:2,
and 1:4. The cells were incubated for 96 hours in a humidi-
ﬁed incubator at 37°C with 5% CO2. Cells were pulsed with
1 µCi of 3H-thymidine (Dupont-NEN, Boston, MA) and
further cultured for 16 to 18 hours. Samples were counted
in a β counter. As control populations, responders and stim-
ulators were cultured alone. The proliferation index was cal-
culated as follows:
Responder + Stimulator
Stimulator alone
FACS-Based Killing Assay
An adaptation of a FACS-based assay was performed as
described [26] to evaluate target-cell death in mixed-cell
cultures. Brieﬂy, expanded CD8+ NK-T cells at days 14 to
21 of culture (effectors) were washed with PBS and resus-
pended in cRPMI at 2 × 106/mL. Targets included tumor
cells (EL-4 [H-2b] and BCL1 [H-2
d]) or freshly isolated
bone marrow from C57BL/Ka.Thy-1.1 (H-2b) and BALB/c
(H-2d) mice. Bone marrow was harvested as above and red
blood cells were removed with osmotic lysis (ACK). Targets
were labeled with the membrane dye PKH-26 red (Sigma,
St. Louis, MO) according to the manufacturer’s guidelines
and were added to effectors at an effector-to-target (E:T)
ratio of 10:1. After 18 hours of coculture, cells were stained
with annexin V (R&D Systems, Minneapolis, MN) and PI
and analyzed by FACS. Effector cells were distinguished
from tumor targets on the basis of PKH-26 expression. Live
and dead cells were distinguished using annexin V and PI.
Speciﬁc apoptosis was calculated as:
Experimental apoptosis – Baseline apoptosis
× 100
100 – Baseline apoptosis
Chromium-Release Assay
Targets cells, BCL1 (H-2
d) and EL4 (H-2b), were
labeled with 51Cr (Dupont-NEN, Boston, MA) by incubat-
ing 1 to 2 × 106 cells with 300 µCi 51Cr for 2 hours at 37°C.
The labeled cells were washed with PBS 3 times, then dis-
tributed in 96-well plates at 2 × 104 cells/well in triplicate.
Effector cells were added at a 10:1 effector to target (E:T)
ratio and incubated for 4 hours at 37°C. The cells were then
pelleted by centrifugation, and aliquots of supernatant were
counted in a γ counter. The percentage of specific 51Cr
release was calculated according to the following formula:
Test release – Spontaneous release
Maximal release – Spontaneous release
× 100
Maximum 51Cr release was determined by incubation of
target cells in 2% NP40.
RESULTS
To obtain the expanded cell population mouse spleno-
cytes cultured for the ﬁrst 24 hours with IFN-γ underwent
initial activation with plate-bound anti-CD3 antibody and
rhIL-2. The cells were then maintained in culture media
supplemented with rhIL-2. After 21 days, the resultant pop-
ulation had the morphology of activated lymphoblasts (Fig-
ure 1A). Many of the cells were large (16-20 microns) with
abundant cytoplasm and numerous cytoplasmic granules. By
day 21 of culture, the majority of cells (>95%) coexpressed
CD3, CD8, and TCRα/β, and a significant proportion
(50%-60%) expressed the NK-cell markers (NK1.1 and DX5)
(Figure 1B). For the studies described below, the unseparated
bulk population of expanded CD8+ NK-T cells was used.
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GVHD Studies
Expanded CD8+ NK-T cells produce large amounts of
T-helper cell type 1 cytokines [21], which are implicated in
causing acute GVHD [9]. To determine whether these cells
will cause GVHD, we performed in vivo cotransfer studies
with puriﬁed HSCs. HSCs from C57BL/Ka.Thy-1.1 mice
were transferred with expanded CD8+ NK-T cells also
derived from C57BL/Ka.Thy-1.1 mice into lethally irradi-
ated MHC-mismatched BALB/c recipients. The dose of
stem cells transferred was sufficient to rescue all recipient
mice from the effects of irradiation [27]. Figure 2A shows the
body weights of mice that received the highest expanded
CD8+ NK-T–cell dose (107 cells); these body weights are
compared with the body weights of mice that received HSCs
plus naive splenocytes (106 cells) or HSCs alone. As shown,
all mice lost weight following lethal irradiation. Mice that
received naive splenocytes rapidly died within the first
2 weeks posttransplantation due to acute GVHD. In con-
trast, mice that received HSCs alone or HSCs plus expanded
CD8+ NK-T cells regained weight in the subsequent 2 to
3 weeks. Although there was a decrease in the weights of
mice that received expanded CD8+ NK-T cells, these ani-
mals were grossly indistinguishable from those that received
HSCs alone. The mice appeared healthy, rarely had evidence
of diarrhea or rufﬂed fur, and all survived (Figure 2B). Mice
that received <107 expanded CD8+ NK-T cells/mouse showed
no differences in their weights compared to the weights of
control mice that received transplants of HSCs alone (not
shown). Thus, expanded CD8+ NK-T cells do not cause signiﬁ-
cant acute GVHD, even when administered at high doses.
GVT Activity of Expanded CD8+ NK-T Cells
We previously developed an in vivo assay that models
the clinical situation of persistent malignancy and relapse
following an HCT procedure [15]. BALB/c mice were inoc-
ulated with limited doses of the B-cell lymphoma, BCL1,
which were allowed to grow for 1 week, and then received
lethal irradiation and transplants of either purified allo-
geneic HSCs or HSCs plus candidate GVT-conferring pop-
ulations. BCL1-inoculated mice rescued with allogeneic
HSCs alone died from persistent lymphoma. In contrast,
mice infused with HSCs plus GVT-conferring populations
were rescued from lymphoma-mediated death [15]. To test
the antitumor activity of allogeneic expanded CD8+ NK-T
cells we performed HSC transplantations as above, with or
without the addition of 107 expanded cells. As shown in Fig-
ure 2C, expanded CD8+ NK-T cells from C57BL/Ka.Thy-
1.1 mice have signiﬁcant GVT activity (P < .001) consider-
ing that approximately 50% of BCL1-inoculated BALB/c
mice survived long-term, whereas all tumor-inoculated mice
that received HSCs alone died. The cause of death was lym-
phoma in all cases (massive hepatosplenomegaly). Other
control mice included those inoculated with BCL1 alone
that died from lymphoma and a group of non–tumor-
inoculated mice that received transplants of HSCs and had
100% survival (not shown). There was minimal to no evi-
dence of acute GVHD as assessed by weight loss, diarrhea,
or ruffled fur. Thus, expanded CD8+ NK-T cells have
signiﬁcant GVT effects and do not cause signiﬁcant, lethal
GVHD even when transplanted across MHC barriers.
Persistence of Expanded CD8+ NK-T Cells In Vivo
Expanded CD8+ NK-T cells undergo 2 to 3 weeks of
ex vivo stimulation prior to transplantation. To determine
the life span of expanded cells in vivo, Thy-1 congenic
C57BL/Ka.Thy-1.2 donors were used to allow differentia-
tion of the origin of HSCs versus expanded CD8+ NK-T
cells. BALB/c recipients were inoculated with BCL1 and,
Figure 1. Morphology and surface phenotype of expanded CD8+ NK-T cells. A, Wright-Giemsa stain of expanded CD8+ NK-T cells at day 21 of
culture showing large, activated cells with foamy cytoplasm and granules. B, FACS analysis reveals a homogenous population of
CD3+CD8+TCRα/β+ cells, with approximately 50% of the cells expressing the NK-cell marker, NK1.1. Data represent 3 or more experiments on
>20,000 live events.
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1 week later, received transplants of allogeneic HSCs plus
CD8+ NK-T cells from the congenic donors. Three weeks
posttransplantation, the peripheral blood of recipient mice
was tested for Thy-1 allotype and donor HSC chimerism.
Figure 3 shows FACS plots from mice that received either
HSCs alone or HSCs plus congenic expanded CD8+ NK-T
cells. As shown, mice that received HSCs alone had a single
population that stained positive for Thy-1.2 and negative
for H-2b, indicating host-type T cells. In contrast, mice that
received both HSCs plus expanded CD8+ NK-T cells had
2 populations that expressed Thy-1.2: one that was H-2b
negative (host) and another that was H-2b positive (donor
expanded CD8+ NK-T cells). The ﬁgure shows that the rel-
ative numbers of persistent expanded CD8+ NK-T cells
were variable among individual mice ranging from 1.7% to
15% of the total mononuclear-cell fraction.
Proliferation and Cytotoxicity Against Allogeneic
Targets
To investigate the alloreactivity of expanded CD8+ NK-T
cells, we performed in vitro proliferation assays (mixed lym-
phocyte reactions) against nontumor allogeneic stimulator
cells. Responder cells were splenocytes cultured under the
conditions of IFN-γ, anti-CD3 MoAb, and rIL-2 as
described, whereas stimulator cells were irradiated spleno-
cytes from MHC-disparate mice. The proliferative activity of
responder cells cultured in the presence or absence of allogeneic
stimulators was tested at the beginning of culture (day 0)
Figure 2. Effect of high doses of CD8+ NK-T cells on recipient body weight and GVT activity. A and B, BALB/c mice (H-2d) were lethally
irradiated (400 cGy × 2) and rescued with hematopoietic cell grafts that differed in cell content. Control mice received 6000 FACS-purified
HSCs (n = 5, ) derived from C57BL/Ka.Thy-1.1 mice (H-2b) either alone, or with 107 naive splenocytes (n = 5, ). Mice in the treatment
group received purified HSCs from C57BL/Ka.Thy-1.1 donors plus titrated doses (104 to 107) of expanded CD8+ NK-T cells also derived from
C57BL/Ka.Thy-1.1 (H-2b) mice. Shown are the average body weights (A) and the survival (B) of mice that received the highest dose (107) of
CD8+ NK-T cells (n = 5, ). C, Kaplan-Meier analysis showing significantly prolonged survival (P < .001) of tumor-bearing BALB/c (H-2d) mice
that underwent lethal irradiation followed by transplantation with 6000 purified HSCs plus 107 expanded CD8+ NK-T cells derived from
C57BL/Ka.Thy-1.1 mice (n = 14, ) compared to mice that received C57BL/Ka.Thy-1.1 HSCs alone (n = 15, ). Control mice included those
that received lethal irradiation, but no stem-cell rescue (n = 5, ). Of note, all mice that died in either the HSC-control or the expanded CD8+
NK-T–cell groups succumbed to tumor (massive hepatosplenomegaly) compared with the radiation-control group that died of marrow aplasia.
Results are combined from 2 independent experiments.
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and then weekly for 3 weeks. At baseline, the responder
population continuously proliferated under the inﬂuence of
rhIL-2; therefore, responses to stimulators were assessed
above the baseline proliferation rate. Figure 4A shows that
responder splenocytes mixed with allogeneic stimulator cells
on day 0 demonstrate signiﬁcant proliferation above back-
ground, whereas at all subsequent time points no increased
proliferation was observed. In fact, by day 21, exposure to
allogeneic cells appeared to suppress proliferation. In con-
trol experiments, syngeneic stimulators were added at the
above time points and there was minimal proliferation above
baseline at day 0, but no increase thereafter (not shown).
To determine the relative speciﬁcity of expanded CD8+
NK-T cells toward tumor targets versus normal BM, we
performed killing assays against both syngeneic and allo-
geneic normal BM or tumor targets. Using 51Cr-release
assays, we could not detect cytotoxicity against normal bone
marrow, which may have been due to poor 51Cr labeling of
targets (not shown). For this reason, we also used an 18-hour
FACS-based killing assay where targets are labeled with a
membrane dye (PKH26) and apoptosis is measured by
annexin V and PI [28]. Using this method, we found potent
cytotoxicity against both syngeneic (H-2b) and allogeneic
(H-2d) tumor targets. There was also toxicity against allo-
geneic bone marrow, but minimal to no cytotoxicity against
syngeneic bone marrow (Figure 4B).
Expression of Ly-49, CD94, and NKG2A/C/E
NK cells mediate GVT without GVHD when trans-
planted across MHC barriers [29]. This GVT activity may
be due to the lack of engagement of inhibitory class I recep-
tors (Ly-49 and NKG2A/C/E) on the donor cells that sub-
sequently trigger cytolysis. Because expanded CD8+ NK-T
cells share features of NK cells (expression of NK1.1 and
DX5, and MHC-unrestricted cytotoxicity), we investigated
the expression of these molecules on unactivated splenocytes
and expanded CD8+ NK-T cells. Using multicolor FACS
analysis, we found that a signiﬁcant proportion (2% to 7%)
of CD3+CD8+TCRα/β+ splenocytes express 1 of the Ly49
molecules (A, C, D, F, G, and I) (Figure 5A). Conversely, after
activation and expansion, few CD8+ NK-T cells expressed
Ly49 family members (<3%).
NK cells also mediate immune surveillance through
CD94/NKG2 heterodimers that recognize the nonclassical
class I molecule, Qa-1, complexed with the leader sequence
of classical class I molecules, referred to as Qdm-1 [30,31].
The NKG2 molecules that heterodimerize with CD94
include NKG2A, NKG2C, and NKG2E, all of which are
identiﬁed by the 20d5 antibody [30]. To evaluate the expres-
sion of these molecules on the surface of unactivated spleno-
cytes and expanded CD8+ NK-T cells, we performed FACS
analysis at day 0 and day 21 of culture. Figure 5B shows
that, at the initiation of cultures (day 0), small numbers
(<3%) of CD3+CD8+TCRα/β+ splenocytes coexpress either
CD94 or NKG2A/C/E, but that after expansion, large
numbers of cells (>50%) express these molecules.
Mechanism of GVT
Perforin and FasL are the principal mechanisms of cyto-
toxic T lymphocyte–mediated antitumor cytotoxicity [32].
To determine the cytotoxic mechanism used by expanded
CD8+ NK-T cells, we generated expanded CD8+ NK-T
cells from mice that either lacked perforin (pfp-KO) or were
defective in FasL (gld). Expanded CD8+ NK-T cells were
generated from either animal and were phenotypically simi-
lar to expanded CD8+ NK-T cells from wild-type (WT)
animals. Figure 6A shows that the in vitro antitumor activity
was dependent upon perforin because expanded CD8+ NK-T
cells derived from pfp-KO mice had no cytolytic activity
against tumor cell lines. This lack of activity was in contrast
to cells derived from gld mice that had cytotoxic activity
comparable to cells expanded from WT mice.
Figure 3. Persistence of expanded CD8+ NK-T cells in vivo. Mice underwent transplantations as described in Figure 2. Three weeks following
transplantation, the peripheral blood of recipient mice was analyzed for donor chimerism by FACS using MoAbs against H-2b and Thy 1.2. Each
panel represents the blood chimerism proﬁle of individual mice that received transplants of HSCs only (top row) or HSCs plus CD8+ NK-T cells
(bottom row). H2b+ Thy1.2– cells stain for lymphocytes from transplanted HSCs, whereas H2b+ Thy1.2+ cells represent adoptively transferred,
expanded CD8+ NK-T cells, and H2b–Thy1.2+ cells identify residual host cells. Numbers represent the percentage of total cells analyzed.
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The in vivo antitumor activity of the expanded cells
derived from these immune-defective mice was then stud-
ied. Survival of mice that received transplants of HSCs and
cells expanded from pfp-KO animals was signiﬁcantly short-
ened compared to that of mice receiving expanded cells
from either WT or gld animals (P < .001) (Figure 6B).
Moreover, survival of mice receiving cells from gld mice was
not statistically different from that of mice receiving WT
cells (P = .52). These data indicate that the expanded cells
mediate antitumor activity in a perforin-dependent manner
and are not dependent upon FasL.
DISCUSSION
For patients with hematologic malignancies, allogeneic
HCT functions dually to provide healthy HSCs and
immune effectors with antitumor activity [5-7,20,33]. How-
ever, because the current standard is to infuse unseparated
hematopoietic cell populations, recipients may develop
GVHD in addition to beneﬁting from GVT effects. In the
present report, we describe the antitumor activity of an ex
vivo expanded population of CD8+ NK-T cells derived from
mouse splenocytes that can be generated in large numbers
and that causes little or no GVHD.
The expanded cells have the surface phenotype of an
otherwise rare population that coexpresses CD3+, CD8+,
and TCRα/β with a signiﬁcant fraction of cells expressing
NK-cell markers (NK1.1 and DX5). A homologous popula-
tion can be expanded from human PBLs [17,22]. Prior stud-
ies on the lineage origins of human expanded CD8+ NK-T
cells indicate that they arise from progenitor T cells
(CD4–CD8– or CD4+CD8+) or CD8–single positive (CD4–
CD8+) but not from CD4–single positive (CD4+CD8–)
T cells or NK cells (CD3–CD56+) [22]. For both mouse and
human the quantitative increase in CD8+ NK-T cells after
culture is striking—up to >100- to 1000-fold in most cul-
tures [21]. Furthermore, the expanded population is not
derived from the preferential outgrowth of conventional
NK-T (CD3+CD56+) cells [22]. The expanded cells differ
from other in vitro cultured cells, such as lymphokine-
activated killer (LAK) cells and tumor infiltrating lympho-
cytes (TILs). LAK cells do not expand efficiently ex vivo
and the major effectors express conventional NK-cell
markers (CD3–CD56+CD16+) [34,35]. TILs are derived
from malignant tissue specimens, are phenotypically CD3+
CD56–CD8+, and are MHC-restricted, whereas expanded
CD8+ NK-T cells do not have these characteristics [36].
Expanded CD8+ NK-T cells also differ from both CD4+
NK1.1+ and CD4–CD8–NK1.1+ cells, which are character-
ized by expression of the invariant TCR Vα14-Jα281, by
restriction to CD1, and by the production of large amounts
of IL-4 [37,38].
Although animals that received HSCs plus expanded
CD8+ NK-T cells had more weight loss than those receiving
HSCs alone, the vast majority of mice did not have other
overt signs of GVHD (hunchback posture, diarrhea, and
ruffled fur). This observation of significantly diminished
acute GVHD was unexpected. In fact, given their activated
state, the cytokines produced, and strong in vitro cytolytic
activity, these cells should be particularly prone to inducing
GVHD. Thus, it is informative that expanded CD8+ NK-T
cells were well tolerated, even at doses signiﬁcantly greater
than the doses of unfractionated splenocytes or purified
splenic CD8+ cells shown to cause lethal GVHD [39]. Simi-
lar results were observed when the same population of
expanded cells was transplanted in the opposite strain com-
bination (ie, BALB/c into C57BL/6 recipients) as well as
across minor histocompatibility barriers (B10.D2 into
BALB/c) (data not shown).
Multiple characteristics of expanded CD8+ NK-T cells
may explain the decreased propensity for GVHD. At the
time of in vivo transfer, expanded CD8+ NK-T cells have
undergone ex vivo stimulation and are terminally differenti-
ated. Thus, introduction of cultured expanded CD8+ NK-T
cells in vivo does not appear to reproduce the cellular events
Figure 4. Proliferation and cytotoxicity against targets. A, Proliferation
assay: at sequential time points in culture, expanded CD8+ NK-T cells
(H-2b) were combined at a 1:2 ratio with freshly isolated irradiated
splenocytes (3000 cGy) from allogeneic (H-2d) BALB/c mice. The pro-
liferation index was calculated for each time point (see Methods). Similar
results were obtained at other ratios (1:1 and 1:4) and without rIL-2 (not
shown). No increase in proliferation was observed against syngeneic tar-
gets (not shown). B, FACS-based killing against tumor targets and BM:
expanded CD8+ NK-T cells were combined with PKH-26 red–labeled
tumor targets (BCL1 [H-2
d], EL-4 [H-2b]) or BM (from C57BL/6 [H-2b],
or Balb/c [H-2d]) at an E:T ratio of 10:1 and incubated for 18 hours.
Effector cells were differentiated from tumor targets on the basis of
PKH-26 expression (forward-light scatter [FL]-2). Live and dead cells
were distinguished using annexin V and PI (FL-1 and FL-3, respec-
tively). Data are derived from >100,000 events/sample performed in trip-
licate. Results are representative of 3 or more experiments.
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that occur with naive cells (ie, T-cell activation). Further-
more, we have found no rhIL-2 messenger RNA (mRNA)
transcripts using an RNase protection assay, and expanded
CD8+ NK-T cells remain dependent upon exogenous rhIL-
2 because removal of rhIL-2 leads to a decrease in cell via-
bility and antitumor activity (unpublished observations).
Expanded CD8+ NK-T cells make a variety of cytokines,
which may also explain their attenuated GVHD. Expanded
CD8+ NK-T cells make large quantities of tumor growth
factor–β (TGF-β) mRNA [21]. TGF-β in combination with
IL-10 renders CD4+ T cells hyporesponsive to alloantigen
and signiﬁcantly reduces their propensity to induce GVHD
Figure 5. Expression of Ly49, CD94, and NKG2A/C/E in unstimulated CD3+, CD8+, and TCRα/β+ splenocytes and in expanded CD8+ NK-T cells.
Freshly isolated cells (day 0 splenocytes) or day 21 expanded CD8+ NK-T cells were stained with ligand-speciﬁc antibodies and analyzed using multicolor
FACS analysis. Dead cells were excluded using PI. For day 0 cells, gates were placed on the CD3+, CD8+, and TCRα/β+ cells as shown (A). Because
day 21 expanded CD8+ NK-T cells are >95% CD3+, CD8+, and TCRα/β+, multicolor FACS analysis was not required. Data were collected on >400,000
or 50,000 events for unstimulated (day 0) or expanded CD8+ NK-T cells (day 21), respectively. Results are representative of 3 or more experiments.
M.R. Verneris et al.
540
[40]. In fact, in addition to TGF-β we can detect IL-10
transcripts using an RNase protection assay and low levels
of IL-10 protein upon phytohemagglutinin stimulation [21].
Whether this same cytokine combination induces a similar
hyporesponsiveness in CD8+ cells and whether the amount
of IL-10 secreted by expanded CD8+ NK-T cells is suffi-
cient in inhibiting GVHD remain to be formally shown. Of
note, the hyporesponsiveness induced by TGF-β and rhIL-10
could be partially overcome by the addition of exogenous
IL-2 [40], which was used when the cells were cultured in
our study. Another cytokine that might also influence the
development of GVHD is IFN-γ. Expanded CD8+ NK-T
cells constitutively secrete IFN-γ at high levels [21] and,
although this cytokine has been implicated as causative of
GVHD [41], recent studies by Yang et al. [42] showed that
IFN-γ protects against GVHD in the early phases post-
transplantation. Moreover, expanded CD8+ NK-T cells
derived from mice deﬁcient in IFN-γ induce rapid and lethal
acute GVHD [21].
Expanded CD8+ NK-T cells induce minimal GVHD, but
demonstrate significant GVT activity. Here we show that
transplantation of allogeneic HSCs plus CD8+ NK-T cells
rescues approximately 50% of lymphoma-bearing animals
compared with transplantation of allogeneic HSCs alone,
which have no GVT activity. Expanded CD8+ NK-T cells
persist in the peripheral circulation of animals for up to 3 weeks
posttransfer. In subsequent experiments, we were unable to
detect the adoptively transferred CD8+ NK-T cells in periph-
eral circulation at 35 to 40 days posttransfer (data not shown).
Whether these cells have migrated to the peripheral tissues or
undergone apoptosis is not known at this time.
Here, we observed that an intact perforin pathway was
required for expanded CD8+ NK-T cells to kill BCL1 tumor
targets, whereas deficiency in FasL had no measurable
effect. Perforin mRNA is expressed at high levels in ex vivo
expanded human CD8+ NK-T cells (unpublished observa-
tions). The relative contributions to the GVT effect of per-
forin- versus FasL-dependent pathways have been reported
elsewhere by our group [15] and others [39,43,44]. Results
differed among studies, leading us to conclude that GVT
activity depends upon the tumor type and form of cellular
therapy administered [45,46]. The most relevant example
that different cell populations use different cellular pathways
comes from our prior studies wherein the source of GVT-
conferring cells was the only variable. Using the same in
vivo model as described here, we tested the GVT effects of
naive CD8+ splenocytes (rather than expanded CD8+ NK-T
cells). In contrast to the results of current studies, we found
that naive CD8+ splenocytes required both perforin and
FasL pathways for antitumor activity [15], whereas expanded
CD8+ NK-T cells use only perforin.
Expanded CD8+ NK-T cells preferentially kill tumor tar-
gets rather than normal BM. At an E:T ratio of 10:1,
expanded CD8+ NK-T cells from C57BL/6 (H2b) mice dis-
played minimal to no cytotoxicity against autologous BM, but
mediate potent antitumor activity against autologous tumor
targets. In the allogeneic situation, expanded CD8+ NK-T
cells from C57BL/6 (H2b) mice readily killed both BM and
tumor targets from BALB/c (H2d) animals. In all cases, the
killing of the BM was reduced compared to that of the tumor
targets, suggesting speciﬁcity for malignant cells. The obser-
vation that perforin is necessary for expanded CD8+ NK-T
cell–mediated antitumor cytotoxicity suggests that direct tar-
get-cell contact is necessary. To date, only disruption of the
lymphocyte function–associated antigen-1 (LFA-1) and inter-
cellular adhesion molecule-1 (ICAM-1) interaction has been
shown to inhibit expanded CD8+ NK-T cell–cytotoxic activ-
ity [17]. However, identiﬁcation of the receptor/ligand pairs
used by expanded CD8+ NK-T cells to recognize targets is
incomplete. Expanded CD8+ NK-T–cell cytolytic activity is
not blocked by antibodies against MHC class I molecules on
target cells or by antibodies against the TCRα/β [17] or NK1.1
(data not shown). In addition, CD1 recognition does not play
a role in either expansion or cytotoxicity [21].
In an attempt to characterize the mechanism of target
recognition, we evaluated expanded CD8+ NK-T cells for
expression of the recently identiﬁed members of the Ly49
Figure 6. Expanded CD8+ NK-T cells mediate GVT via a perforin-
dependent mechanism. A, In vitro 51Cr-release assay using expanded
CD8+ NK-T cells derived from either WT, perforin-knockout (pfp-
KO), or FasL-deficient (gld) C57BL/6 (H-2b) mice as responders.
Lymphoma-tumor targets were BCL1 (H-2
d) or EL-4 (H-2b). E:T ratio
shown is 10:1. Similar results were obtained at E:T ratios of 5:1, 20:1,
and 40:1 (not shown). Results are representative of 3 or more indepen-
dent experiments. B, BCL1-inoculated BALB/c mice were received
transplants (as in Figure 2) of 6000 FACS-purified HSCs plus
107 expanded CD8+ NK-T cells derived from either pfp-KO (n = 13,
), or gld (n = 13, H17009) C57BL/6 splenocytes. Control mice included
BCL1-inoculated BALB/c mice that underwent transplantation and res-
cue with C57BL/6 HSCs alone (n = 5, ) or non–tumor-inoculated
mice that received irradiation only (n = 5, ).
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and NKG2 families. Whereas small numbers of CD3+CD8+
TCRα/β+ splenocytes (at day 0) express Ly49, we found
almost no expression of Ly49 molecules A, C, D, F, G, and I
on expanded CD8+ NK-T cells. Ly49 molecules have previ-
ously been identified on splenic memory CD8+ cells, and
engagement of Ly49 by MHC class I molecules inhibits
T-cell receptor–induced activation of these cells [47].
Although TCR signaling is not involved in target recogni-
tion of expanded CD8+ NK-T cells [17], we hypothesize
that other activating receptors are responsible for tumor
recognition, and it is tempting to speculate that down-
regulation of an inhibitory receptor (Ly49) could explain the
enhanced antitumor activity seen after culture.
In contrast to Ly49, we see an increase in the expression
of CD94 or NKG2 staining on expanded CD8+ NK-T cells.
The 20d5 antibody recognizes 3 related NKG2 molecules (A,
C, and E) [30]. These molecules contain highly homologous
extracellular domains (carbohydrate-recognition domains)
and bind to the nonclassical MHC class Ib molecule, Qa-1,
on target cells [30]. The intracellular regions of NKG2A con-
tain immunoreceptor tyrosine-based inhibition motifs
(ITIM), and engagement of NKG2A has been shown to have
inhibitory function on NK cells [31,48]. In contrast, the
intracellular domains of NKG2C and NKG2E lack ITIM,
suggesting that they have activating functions [30]. At pres-
ent, reagents that allow the separation of cells expressing the
inhibitory receptors (NKG2A) from those expressing the
activating receptors (NKG2C and NKG2E) are not yet avail-
able. Thus, although there is an increase in 20d5-staining
cells, it is unclear whether this represents the activating or
inhibiting forms (or both) of the CD94/NKG2 heterodimer.
When such reagents are available, distinguishing cell popula-
tions with the activating and/or inhibiting forms of this het-
erodimer will be the subject of future studies.
In conclusion, technological advances in cell separation
have permitted the design of hematopoietic grafts that can
confer the benefits of allogeneic HCT with significantly
reduced risks. Yet practical concerns still limit the use of these
technologies for patient care. Here we described the in vivo
activity of ex vivo expanded CD8+ NK-T cells transplanted
with puriﬁed HSCs, conferring GVT effects with minimal
GVHD. Other features that make these cells attractive for
clinical use are that they can be obtained in large numbers
and have a ﬁnite in vivo life span, obviating the need to engi-
neer elimination of potentially harmful long-lived expanded
CD8+ NK-T cells. In addition, because the cells expand after
multiple rounds of proliferation, they are amenable to manip-
ulation by gene targeting. Candidate genes include those that
might improve homing and/or killing activity. Currently,
phase I clinical trials involving expanded autologous CD8+
NK-T cells are underway. We look forward to a future when
engineered hematopoietic grafts such as those proposed here
will be used to limit morbidity and confer maximum beneﬁt
to patients undergoing hematopoietic cell transplantation.
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